Eli Lilly CFO Credits Mounjaro, Zepbound and FX for 56% Revenue Beat
Eli Lilly delivered a 56% year-over-year revenue beat, led by Mounjaro weight-loss therapy sales of $3.4 billion and initial Zepbound obesity drug revenue of $200 million. The CFO highlighted double-digit growth in Trulicity and Jardiance, favorable foreign exchange adding 4 percentage points and disciplined cost management.
1. Key Drivers of Revenue Beat
CFO Lucas Montrace pointed to Mounjaro’s $3.4 billion in sales and Zepbound’s $200 million launch revenue as the primary factors behind the 56% year-over-year revenue beat. He noted that robust uptake of obesity and weight-management therapies outpaced internal expectations.
2. Diabetes Franchise Performance
Trulicity and Jardiance each posted double-digit sales growth, contributing significantly to overall revenue expansion. The diabetes portfolio’s momentum underscored sustained demand for Eli Lilly’s established treatments.
3. Foreign Exchange and Cost Management
Favorable foreign exchange rates boosted reported revenue by approximately 4 percentage points. Montrace also emphasized disciplined expense controls, which helped preserve operating margins despite rapid top-line growth.